Video

Dr. Van Zee on Estimating Risk For Surgical Options in DCIS

Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ.

Kimberly Van Zee, MD, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the various surgical options for patients with ductal carcinoma in situ (DCIS).

Individualizing treatment for patients with breast cancer has become more important in recent years, says Van Zee. DCIS is somewhat paradoxical in its nature, as there is essentially no risk of metastatic disease or death. However, it also has a higher local recurrence rate in the breast than does invasive cancer.

When it comes to surgical treatment, the options are quite broad, explains Van Zee. They can range from wide excision alone, wide excision with radiation, or with endocrine therapy, to mastectomy or bilateral mastectomy. Overall, it is important to assess a patient's individual values to determine what treatment option is best for her.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD